IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?

IHE pays a meaningfully higher dividend yield than BBH. BBH offers more concentrated exposure with 25 holdings, compared to 56 for IHE.

The Motley Fool • Jul 19, 2026

Invesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?

Invesco S&P 500 Equal Weight Health Care ETF provides broader exposure with 60 holdings compared to the 25 positions in VanEck Biotech ETF VanEck Biotech ETF has a slightly lower expense ratio of 0.35% while Invesco S&P 500 Equal Weight Health Care ETF charges 0.40% Invesco S&P 500 Equal Weight Health Care ETF has experienced a significantly lower five-year maximum drawdown than the biotech fund

The Motley Fool • Jul 14, 2026

Should You Invest in the VanEck Biotech ETF (BBH)?

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the VanEck Biotech ETF (BBH) is a passively managed exchange traded fund launched on December 20, 2011.

Zacks Investment Research • Jul 13, 2026

Which is the Better Choice for Healthcare Investors? IYH or BBH?

iShares U.S. Healthcare ETF provides broader exposure with 100 holdings compared to the 25 found in VanEck Biotech ETF VanEck Biotech ETF has delivered higher recent total returns but carries significantly greater historical price volatility iShares U.S. Healthcare ETF offers a higher dividend yield and lower five-year maximum drawdown for income-focused investors

The Motley Fool • Jul 11, 2026

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

State Street SPDR S&P Pharmaceuticals ETF provides exposure to 65 companies compared to the 25 holdings in VanEck Biotech ETF. VanEck Biotech ETF has experienced a deeper maximum drawdown of almost 40% over the last five years.

The Motley Fool • Jul 8, 2026

FHLC vs. BBH: Which Healthcare ETF Is the Better Buy?

Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.

The Motley Fool • Jul 4, 2026

Investors Are Rotating Into Healthcare. Here's Why.

Janus Henderson portfolio manager Dan Lyons discusses why he sees opportunities for market outperformance in the healthcare sector as innovations in biotechnology, pharmaceuticals and medical devices proliferate. Check out our daily newsletter!

Investors Business Daily • Jul 2, 2026

BIO CEO says more consistency needed in FDA review process

U.S. biotechnology industry trade group BIO worked with the Food and Drug ​Administration on plans announced on Monday to speed ‌clinical trials and expects the next initiative will aim to standardize the agency's review of drug applications, CEO John Crowley ​said on Tuesday.

Reuters • Jun 23, 2026

Biotech ETFs Gain Momentum via AI Drug Discovery & Surging M&A

The biotechnology sector has broken out of its multiyear bear market. As macroeconomic headwinds moderate and regulatory environments stabilize, biotech ETFs are surging.

ETF Trends • Jun 23, 2026

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

Zacks Investment Research • Jun 10, 2026